AxoGen, Inc. (AXGN)
- Previous Close
6.87 - Open
6.72 - Bid 6.47 x 100
- Ask 6.54 x 200
- Day's Range
6.46 - 6.87 - 52 Week Range
3.45 - 10.83 - Volume
168,386 - Avg. Volume
383,648 - Market Cap (intraday)
284.844M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.51 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 27, 2010
- 1y Target Est
13.67
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
www.axogeninc.comRecent News: AXGN
Performance Overview: AXGN
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXGN
Valuation Measures
Market Cap
300.13M
Enterprise Value
338.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.85
Price/Book (mrq)
3.14
Enterprise Value/Revenue
2.13
Enterprise Value/EBITDA
-25.39
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.66%
Return on Assets (ttm)
-6.84%
Return on Equity (ttm)
-22.08%
Revenue (ttm)
159.01M
Net Income Avi to Common (ttm)
-21.72M
Diluted EPS (ttm)
-0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
31.02M
Total Debt/Equity (mrq)
75.55%
Levered Free Cash Flow (ttm)
-10.5M